Shanghai MicuRx Pharmaceutical (SHA:688373), a US subsidiary of Shanghai MicuRx Pharmaceutical, has filed a lawsuit against Medpace in an Ohio federal court over alleged contract breaches related to a clinical trial agreement, according to a Wednesday filing with the Shanghai bourse.
The dispute stems from Medpace's failure to meet agreed targets and refusal to return trial data. While a partial settlement was reached, unresolved claims remain, the filing said.
The financial impact is uncertain, and the case has yet to go to trial.